Inflammatory Bowel Diseases: Does One Histological Score Fit All?

Mucosal healing (MH) is the main treatment target in ulcerative colitis (UC) and Crohn’s disease, and it is defined by the combination of complete endoscopic and histologic remission. The complete resolution of mucosal inflammation should be confirmed by histology but its assessment is not always univocal. Neutrophil infiltration represents the unique histological marker in discriminating the active vs. quiescent phases of the disease, together with crypt injuries (cryptitis and crypt abscesses), erosions, and ulcerations. On the contrary, basal plasmacytosis is not indicative of activity or the remission of inflammatory bowel diseases (IBDs) but instead represents a diagnostic clue, mostly at the onset. Several histological scoring systems have been developed to assess grade severity, particularly for UC. However, most are complex and/or subjective. The aim of this review was to summarize available scores, their characteristics and limitations, and to present the advantages of a simplified mucosa healing scheme (SHMHS) based on neutrophils and their distribution in the gut mucosa. Finally, we overview future developments including artificial intelligence models for standardization of disease assessments and novel molecular markers of inflammation with potential application in diagnostic practice.

[1]  E. Grisan,et al.  Artificial Intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis. , 2023, Gastroenterology.

[2]  C. Riccardi,et al.  Association of GILZ with MUC2, TLR2, and TLR4 in Inflammatory Bowel Disease , 2023, International journal of molecular sciences.

[3]  M. Fassan,et al.  Correction to: Simplified Histologic Mucosal Healing Scheme (SHMHS) for inflammatory bowel disease: a nationwide multicenter study of performance and applicability , 2022, Techniques in Coloproctology.

[4]  Jakob Nikolas Kather,et al.  Artificial intelligence in histopathology: enhancing cancer research and clinical oncology , 2022, Nature Cancer.

[5]  C. Riccardi,et al.  The novel role of glucocorticoid-induced leucine zipper as a marker of mucosal healing in inflammatory bowel diseases. , 2022, Pharmacological research.

[6]  A. Beck,et al.  Artificial Intelligence Enables Quantitative Assessment of Ulcerative Colitis Histology , 2022, medRxiv.

[7]  Lirsac Marion,et al.  Histological Indices and Risk of Recurrence in Crohn's Disease: A Retrospective Study of a Cohort of Patients in Endoscopic Remission. , 2022, Inflammatory bowel diseases.

[8]  E. Grisan,et al.  PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system , 2022, Gut.

[9]  L. Peyrin-Biroulet,et al.  ECCO Position on harmonization of Crohn's disease mucosal histopathology. , 2022, Journal of Crohn's & colitis.

[10]  C. Riccardi,et al.  A recombinant glucocorticoid‐induced leucine zipper protein ameliorates symptoms of dextran sulfate sodium‐induced colitis by improving intestinal permeability , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Jakob Nikolas Kather,et al.  Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review. , 2021, European journal of cancer.

[12]  R. Pai,et al.  Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis. , 2021, Inflammatory bowel diseases.

[13]  V. Villanacci,et al.  Histopathology of IBD Colitis. A practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD) , 2021, Pathologica.

[14]  A. Griffiths,et al.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. , 2020, Gastroenterology.

[15]  A. Ananthakrishnan,et al.  Treat to target: The role of histologic healing in inflammatory bowel diseases: A systematic review and meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  L. Peyrin-Biroulet,et al.  ECCO Position Paper: Harmonisation of the approach to Ulcerative Colitis Histopathology. , 2020, Journal of Crohn's & colitis.

[17]  M. Cravo,et al.  Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels. , 2020, Journal of Crohn's & colitis.

[18]  J. Cotter,et al.  Comparison of the Nancy index with continuous Geboes score: histological remission and response in ulcerative colitis. , 2020, Journal of Crohn's & colitis.

[19]  D. Rubin,et al.  Histologic Healing is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  M. Gurcan,et al.  Digital pathology and artificial intelligence. , 2019, The Lancet. Oncology.

[21]  C. Riccardi,et al.  How Glucocorticoids Affect the Neutrophil Life , 2018, International journal of molecular sciences.

[22]  V. Villanacci,et al.  Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy , 2018, Techniques in Coloproctology.

[23]  F. Rieder,et al.  The emerging role of histologic disease activity assessment in ulcerative colitis. , 2018, Gastrointestinal endoscopy.

[24]  C. Riccardi,et al.  GILZ restrains neutrophil activation by inhibiting the MAPK pathway , 2018, Journal of leukocyte biology.

[25]  I. Nagtegaal,et al.  Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion , 2018, Journal of Crohn's & Colitis.

[26]  V. Villanacci,et al.  Usefulness of Different Pathological Scores to Assess Healing of the Mucosa in Inflammatory Bowel Diseases: A Real Life Study , 2017, Scientific Reports.

[27]  K. Geboes,et al.  Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology? , 2017, Virchows Archiv.

[28]  B. Feagan,et al.  Histologic scoring indices for evaluation of disease activity in ulcerative colitis. , 2017, The Cochrane database of systematic reviews.

[29]  A. Sapino,et al.  Eosinophilia – associated basal plasmacytosis: an early and sensitive histologic feature of inflammatory bowel disease , 2017, Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS).

[30]  C. Rosty,et al.  Histopathological findings of extra-ileal manifestations at initial diagnosis of Crohn’s disease-related ileitis , 2016, Virchows Archiv.

[31]  B. Sands,et al.  Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  S. Vermeire,et al.  A Simplified Geboes Score for Ulcerative Colitis , 2016, Journal of Crohn's & colitis.

[33]  G. D'Haens,et al.  Histologic scoring indices for evaluation of disease activity in Crohn's disease. , 2016, The Cochrane database of systematic reviews.

[34]  S. Anita,et al.  Histological activity and basal plasmacytosis are nonpredictive markers for subsequent relapse in ulcerative colitis patients with mucosal healing , 2016 .

[35]  L. Stitt,et al.  Development and validation of a histological index for UC , 2015, Gut.

[36]  S. Travis,et al.  Development and validation of the Nancy histological index for UC , 2015, Gut.

[37]  B. Warren,et al.  Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up , 2015, Gut.

[38]  C. Langner,et al.  Histological remission in inflammatory bowel disease: where are we, and where are we going? , 2015, Journal of Crohn's & colitis.

[39]  S. Travis,et al.  Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. , 2014, Journal of Crohn's & colitis.

[40]  O. Giouleme,et al.  Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[41]  G. Reboldi,et al.  Endoscopic biopsy samples of naïve "colitides" patients: role of basal plasmacytosis. , 2014, Journal of Crohn's & colitis.

[42]  G. D'Haens,et al.  A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical Trials: Recommendations and Implications for Future Research , 2014, Inflammatory bowel diseases.

[43]  M. Vandervoort,et al.  Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices , 2014, Inflammatory bowel diseases.

[44]  G. Petris,et al.  The histopathological approach to inflammatory bowel disease: a practice guide , 2014, Virchows Archiv.

[45]  G. Petris,et al.  European consensus on the histopathology of inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[46]  P. Rutgeerts,et al.  Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing , 2012, The American Journal of Gastroenterology.

[47]  M. Neurath,et al.  Mucosal healing in inflammatory bowel diseases: a systematic review , 2012, Gut.

[48]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[49]  C. O'Morain,et al.  Review article: defining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.

[50]  G. Porro,et al.  Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  B F Warren,et al.  European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. , 2008, Journal of Crohn's & colitis.

[52]  N. Harpaz,et al.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. , 2007, Gastroenterology.

[53]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[54]  R. Yantiss,et al.  Diagnostic difficulties in inflammatory bowel disease pathology , 2006, Histopathology.

[55]  S Al-Haddad,et al.  The role of eosinophils in inflammatory bowel disease , 2005, Gut.

[56]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[57]  M F Dixon,et al.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. , 1996, The American journal of surgical pathology.

[58]  C. Bernstein,et al.  Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. , 1995, Gastrointestinal endoscopy.

[59]  R. Pounder,et al.  Early mucosal changes in Crohn's disease. , 1993, Gut.

[60]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[61]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[62]  S. Truelove,et al.  Biopsy Studies in Ulcerative Colitis , 1956, British medical journal.